Search Tufts Medicine

Displaying 1 - 16 of 16
Service
People living with end-stage kidney (renal) disease need extra help filtering out waste and toxic substances as well as regulating blood pressure and pH balance. A kidney transplant adds a healthy kidney to help get your body back on track. ...
Service
When organs like the heart, kidney, liver or bone marrow can no longer perform their most essential functions, transplant surgery can give you back the quality of life you expect and deserve. ...
Service
Did you know that Polycystic Kidney Disease (PKD) is a genetic disorder that you are born with? This condition primarily affects the kidneys and, in some cases, the liver, too. At Tufts Medicine, we understand that personalized treatment is key to living a healthy life. With our expert care, you can take control of your health and enjoy life to the fullest. ...
Service
Managing your blood pressure is an important part of keeping your body healthy, but did you know that having high blood pressure can injure your kidneys?  ...
Service
Your kidneys perform many vital functions, including removing waste, filtering blood and removing excess water and electrolytes. When these bean-shaped organs aren't working properly, it can impact your overall health and lead to serious complications. ...
Service
Amyloidosis is a group of plasma cell diseases where misfolded proteins form clusters that build up on your tissue and organs. These clusters, known as amyloids, can harm some of the body's most important organs like the heart, kidneys and liver, as well as nerves. ...
Service
From minimally invasive hernia repair to organ transplants and open heart procedures, our surgeons have the skills and experience to help get you on the road to better health. ...
Service
Multiple myeloma is a plasma cell cancer that occurs when the plasma cells in your bone marrow produce abnormal antibodies. While multiple myeloma isn’t a curable condition, it’s very treatable with approaches like stem cell transplants and monoclonal antibody therapy. ...
Service
Adjusting to dialysis treatments can be complicated, which is why we make getting dialysis as convenient and comfortable as possible. Your treatment plan is designed with you in mind so you can continue doing what you enjoy. ...
Service
Myeloma (also known as multiple myeloma) and amyloid light-chain (AL) amyloidosis are serious conditions caused by abnormal antibody-producing plasma cells found in the bone marrow where all blood cells are made. While myeloma (a blood cancer) and AL amyloidosis (a blood disease) can develop independently of one another, they’re sometimes diagnosed together. ...
Service
You are so much more than a cancer diagnosis. From proactively taking your health into your own hands with cancer screenings and genetic risk assessments, to challenging cancer with medical innovations and the support of an entire care team, you can trust that Tufts Medicine will go the extra mile in your care journey. ...
Service
Whether you’re looking for information on laboratory tests, requesting lab results or want a second opinion, pathology + laboratory medicine provides comprehensive diagnostic testing services to uncover clues about your body.  ...
clinical trial
...

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
clinical trial
...

This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
clinical trial
...

The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. 

The study will consist of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
clinical trial
...

This is a phase 2, randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of atrasentan vs placebo while on background therapy with SGLT2i in subjects with IgAN. The primary efficacy assessment is the change from baseline in proteinuria (UPCR) at week 12. Eligible subjects who are enrolled in the study will be randomly assigned in a 1 to 1 ratio to either sequence AB or sequence BA.